| Literature DB >> 28560557 |
Marzena Garley1, Ewa Jabłońska2.
Abstract
Neutrophils (PMNs) play a key role in innate defence mechanisms. Generally, PMNs were considered to have a homogeneous population of mature and diversified cells. It seems, however, that their pleiotropic action results from the existence of different subpopulations in this group of cells. There are data that confirm the involvement of PMNs in the direct activation of other cells in non-specific response, as well as specialised cells in specific response. For example, there have been observations of PMNs with different levels of activity in relation to lymphocytes, and a population was identified which had characteristics similar to those of cells which are capable of presenting antigens. There are also reports of PMNs which demonstrate different survival time or capacity for chemotaxis. Other studies suggest that the neutrophil response to Staphylococcus aureus is diverse (not identical among all neutrophil). There are also reports of PMNs with varying activity during inflammation, which might explain many as yet unknown pathophysiological aspects of their hyperreactivity. The functional dualism of PMNs in the course of neoplastic disorders raises a lot of controversy. This paper presents the current state of knowledge of the heterogeneity of PMNs and their potential roles in different stages of disease.Entities:
Keywords: Heterogeneity; Neutrophils; PMNs; Populations; Subpopulations
Mesh:
Year: 2017 PMID: 28560557 PMCID: PMC5767199 DOI: 10.1007/s00005-017-0476-4
Source DB: PubMed Journal: Arch Immunol Ther Exp (Warsz) ISSN: 0004-069X Impact factor: 4.291
Neutrophil subsets
| Neutrophil subset | Immunophenotype | Functional properties | References |
|---|---|---|---|
| Mature/classic | HNA-1 (FcγRIIIb, CD16) | Bux ( | |
| Long-living | HLA-DR, CD80, CD49d | IL-8, IL-1Ra, IL-1-β | Chakravarti et al. ( |
| Aged | CD62LlowCXCR4highCD11BhighCD49high | Phagocytosis, NETosis | Casanova-Acebes et al. ( |
| NBH | BAFF, APRIL | Puga et al. ( | |
| TCR+ | TCRαβ | IL-8 inhibition of apoptosis | Puellmann et al. ( |
| PMN-I | TLR2/TLR4/TLR5/TLR8 | IL-12, CCL3 | Tsuda et al. ( |
| PMN-II | TLR2/TLR4/TLR7/TLR9 | IL-10, CCL2 | |
| PMN-N | TLR2/TLR4/TLR9 | ||
| mPR3+ | mPR3high | Outbreak or progression of chronic inflammatory | Witko-Sarsat et al. ( |
| mPR3+CD177+ | Wegener’s granulomatosis | Bauer et al. ( | |
| CD177 | High, low, negative expression | Wu et al. ( | |
| LDNs | CD66b, CD11b+CD16+ and/or CD11blow/–CD16low/– | Deng et al. ( | |
| LDNs/G-MDSCs | CD66b+CD15+CD14–/dimCD33dimHLA-DR− | Immunosuppressive | Jiang et al. ( |
| LDGs | CD15+/CD14low, CD10+/CD14low, CD16high/CD86− | IFN-γ, TNF-α pro-inflammatory | Denny et al. ( |
| Bone marrow-derived immature neutrophils | CD10low/−CD16low | Manz and Boettcher ( | |
| MDSCs | CD11cbright/CD62Ldim/CD11bbright/CD16bright | Inhibition of T lymphocytes proliferation | Pillay et al. ( |
| MDSCs in cancer | CD14+ CD33+ HLA-DR− | Inhibition of T lymphocytes function | Almand et al. ( |
| N1 | CD11b+/Ly6G+ | Anti-neoplastic activity | Fridlender et al. ( |
| N2 | Pro-neoplastic properties | Jabłońska et al. ( | |
| Proangiogenic | CXCR4high/VEGFR1high | MMP-9 | Christoffersson et al. ( |
IL-1Ra interleukin-1 receptor antagonist, N B-cell helper neutrophils, BAFF B-cell activating factor, APRIL a proliferation-inducing ligand, NETs neutrophil extracellular traps
Fig. 1TANs in response to cancer cells. BAFF B-cell activating factor, APRIL a proliferation-inducing ligand, OSM oncostatin M, HGF hepatocyte growth factor, NE neutrophil elastase, ADCC antibody‐dependent cell‐mediated cytotoxicity
Properties of neutrophils differing neutrophils populations, by Fridlender and Albelda (2012)
| Naive neutrophils | G-MDSC | TANs | |
|---|---|---|---|
| Granule proteins | |||
| Primary | +++ | + | + |
| Secondary | +++ | Mod | + |
| Tertiary | +++ | Mod | + |
| Respiratory burst | |||
| Peroxidase | +++ | +++ | + |
| Reduced nicotinamide adenine dinucleotide phosphate complex | +++ | Mod | + |
| TLR | + | +++ | Mod |
| Structural genes | |||
| Actin binding | Mod | Mod | + |
| Cytoskeleton | Mod | Mod | + |
| Apoptosis | |||
| Intrinsic (BCL2) pathway | Mod | +++ (BH-3) | + |
| NF-κB–antiapoptotic | +++ | + | + |
| Immune system | |||
| Chemokines | + | Mod | +++ |
| Cytokine activity | + | Mod | +++ |
| APC genes | + | +++ | +++ |
+++ high, + low, Mod moderate